Skip to main content
. 2014 Nov 17;9(11):e113250. doi: 10.1371/journal.pone.0113250

Figure 10. PLX Halts Growth of Colon Tumors in Xenograft Models.

Figure 10

CD-1 nu/nu mice were subcutaneously injected with colon cancer cells; HT-29 (p53−/−) on the left flank and HCT116 (p53+/+) on the right flank. (A) Representative tumor size control mice and 50 mg/kg/day vehicle or PLX treated mice, respectively. PLX halted the growth of both HT-29 and HCT116 tumors in-vivo. (B) Average body weights of control and PLX treated mice. The body weights did not vary significantly during the study. Tumor volumes were measured and tumor curve shows the efficacy of 50 mg/kg/day oral administration of PLX. (C) Histopathological analysis of tissue samples obtained from control and PLX-treated animals. Hematoxylin and Eosin stained tissue sections of the livers, hearts, kidneys and tumors. Images were obtained on a bright field microscope at 10× and 63× objective.